HopeStage
Back to all studies
UnknownNCT05294835

Ketamine and Epigenetic Aging

Medication studyAges 18–64United StatesPTSD
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 64 years.

What will I do during this study?

The study group receives ketamine as a study medication.

Listed locations
LexingtonSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: April 1, 2022
Recruitment status
Unknown
Enrollment listed in the registry
20
Sponsor
TruDiagnostic
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 64 Years
Official registry ID
NCT05294835
Official title
Show the full official title

Impact of Ketamine on Epigenetic Age (IKEA)

Recruitment & locations

Status unknown

Lexington

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is TruDiagnostic.

Does this study involve medication?

Yes. The study involves medication, including ketamine.

Who can participate?

Listed age limits: 18 years to 64 years.

Want to explore more studies?

Explore studies